Peps
What is Enlicitide?
Enlicitide is a ring-shaped peptide designed to block PCSK9, the same target as the antibody medicines Repatha and Praluent, but taken as a daily pill instead of an injection. The FDA approved it in July 2026 under the brand name Lipfendra to lower LDL cholesterol in adults with high cholesterol.
Biological role or research focus
LDL cholesterol lowering with a PCSK9-blocking pill.
The trial measured cholesterol levels, not heart attacks, strokes or deaths. Whether enlicitide lowers those events, as the injected PCSK9 antibodies have been shown to, is being tested in a separate outcomes trial that had not reported when this page was checked.
Role reference: A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide · 2026 ↗
Names you may encounter
Enlicitide decanoate · MK-0616 · Lipfendra
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Oral macrocyclic (ring-shaped) peptide that blocks PCSK9; approved by the FDA in July 2026 as Lipfendra
- Research focus
- LDL cholesterol lowering with a PCSK9-blocking pill
- Featured evidence
- Human randomized phase 3 trial
- Source check
- October 4, 2026
Source: A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide · 2026 ↗
Biology & proposed mechanism
PCSK9 is a protein that marks the liver's LDL receptors for destruction. With fewer receptors, less LDL cholesterol is cleared from the blood. Enlicitide binds PCSK9 and stops it attaching to those receptors, so more of them keep recycling and LDL levels fall. Most peptides are broken down in the gut; enlicitide's ring structure and its formulation were engineered so enough is absorbed when swallowed.
Source: A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide · 2026 ↗
Research context & identity
Enlicitide is a prescription medicine for lowering LDL cholesterol, used alongside diet and usually other cholesterol treatment. Its approval is based on LDL lowering; a large outcomes trial is still testing whether it reduces heart attacks and strokes. It is not a research peptide, and PepsRadar does not link to sellers from this page. For how it compares with the antibody and gene-silencing PCSK9 medicines, see the PCSK9 guide linked below.
Source: A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide · 2026 ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized phase 3 trial · 2026
CORALreef Lipids: enlicitide versus placebo for 52 weeks
What did this publication test, and what did it find?
- Population / model
- 2,909 adults who had already had a major atherosclerotic event, or were at risk of a first one, with LDL cholesterol above set thresholds despite their usual treatment. Mean age 63; 39% women.
- Study design
- Multinational, double-blind, placebo-controlled trial. Participants were randomly assigned two to one to enlicitide or placebo for 52 weeks. The main outcome was the percent change in LDL cholesterol at week 24.
- Main finding
- LDL cholesterol fell by about 57% with enlicitide and rose by 3% with placebo at week 24, a difference of about 56 percentage points. Reductions held at week 52, and non-HDL cholesterol, apolipoprotein B and lipoprotein(a) also fell more than with placebo. An earlier phase 2b trial reported reductions of up to about 61% after eight weeks.
- Limits & context
- The trial measured cholesterol levels, not heart attacks, strokes or deaths. Whether enlicitide lowers those events, as the injected PCSK9 antibodies have been shown to, is being tested in a separate outcomes trial that had not reported when this page was checked.
Source: A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide · 2026 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Search additional PubMed records ↗New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Safety & what remains unknown
Adverse events did not appear to differ between enlicitide and placebo over 52 weeks. Longer-term safety and rare effects will come from the ongoing outcomes trial and post-approval monitoring; the prescribing information is the reference for precautions.
Source: A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide · 2026 ↗
Evidence boundaries
The trial measured cholesterol levels, not heart attacks, strokes or deaths. Whether enlicitide lowers those events, as the injected PCSK9 antibodies have been shown to, is being tested in a separate outcomes trial that had not reported when this page was checked.
Source: A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide · 2026 ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
Some seller links are affiliate links, and codes such as PEPSRADAR credit PepsRadar; PepsRadar may earn a commission. Affiliate disclosure. For laboratory research use only. Not for human consumption.
PepsRadar does not link to sellers from this page. It is an experimental compound without human evidence, and research listings are not treatments.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides, Peptide.Express, Offline Peptides, Alera Research, Pinnacle Peptide Labs. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Is enlicitide the same kind of drug as Repatha?
- What material, population, and route were actually studied?
- The trial measured cholesterol levels, not heart attacks, strokes or deaths. Whether enlicitide lowers those events, as the injected PCSK9 antibodies have been shown to, is being tested in a separate outcomes trial that had not reported when this page was checked.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is enlicitide the same kind of drug as Repatha?
They block the same target, PCSK9, but they are very different molecules. Repatha is a large antibody given by injection; enlicitide is a much smaller ring-shaped peptide taken as a pill. Repatha has outcomes-trial evidence of fewer heart attacks and strokes; enlicitide's outcomes trial was still under way when this page was checked.
Source: A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide · 2026 ↗
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
Source: A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide · 2026 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
Antibody, peptide or gene silencer: three ways to block PCSK9 and lower LDL
Repatha, Praluent, Leqvio and the new pill enlicitide all lower LDL cholesterol by targeting the same protein, PCSK9. They are very different kinds of molecules, and only some have been shown to prevent heart attacks and strokes.
Read the guide →